Mankind Pharma Limited
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
3/10
|
47.2 | 59.58 | -20.78% | 50.92 | -7.31% |
| P/S |
|
8.74 | 9.34 | -6.45% |
|
|
| P/BV |
|
9.43 | 6.65 | 41.79% |
|
|
| P/FCF |
|
0.4939 | -112.82 | -100.44% |
|
|
| Ev/Ebitda |
|
32.07 | 141.68 | -77.36% |
|
|
| Ev/S |
|
8.72 | 9.61 | -9.26% |
|
|
| Ev/FCF |
|
50.91 | -85.18 | -159.76% |
|
|
| E/P |
|
2.19 | 0.1137 | 1826.2% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
8/10
|
27.18 | 5.7 | 376.99% | 26.77 | +1.55% |
| ROE |
|
22.77 | 10.72 | 112.36% |
|
|
| ROA |
|
17.65 | 7.64 | 131.06% |
|
|
| ROIC |
|
0 | 15.91 | -100% |
|
|
| ROS |
|
18.51 | -4.5 | -511.27% |
|
|
| ROCE |
|
24.5 | 13.15 | 86.34% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0.0737 | 121.74 | -99.94% | 0.1541 | -52.15% |
| Nеt Debt/Ebitda |
|
-0.0622 | 121.47 | -100.05% |
|
|
| Debt/Ratio |
|
0.0173 | 0.145 | -88.06% |
|
|
| Debt/Equity |
|
0.0221 | 0.3127 | -92.92% |
|
|
| Debt/Net Income |
|
0.1083 | 5.06 | -97.86% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 9.55 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.9146 | -100% | ||
| DSI |
|
0 | 0.8391 | -100% |
|
|
| Average dividend growth |
|
0 | 1.09 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 15.07 | -100% |
|
|
| Average percentage for payments |
|
19.75 | 24.67 | -19.93% |
|
|
| Difference from average difference in sector |
|
-9.55 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
15006.52 | 381.34 | 3835.21% | ||
| Growth impulse Ebitda in 5 years |
|
14833.51 | 402.53 | 3585.07% | ||
| Growth impulse Net Income in 5 years |
|
15815.67 | 642.47 | 2361.7% | ||
| Growth impulse FCF in 5 years |
|
17929.07 | 805.43 | 2126.02% | ||
| Growth impulse EPS in 5 years |
|
15408.5 | 176.76 | 8617.19% |
IP Score
6.17/10
